 |
|
|
| |
Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc in Treatment-Naive Patients
|
| |
| |
Reported by Jules Levin
Glasgow 2010 Nov 7-11
D Chapman1, P Biswas2, M Lewis3, C Craig3, J Heera4, S Ellery4, L Swenson5, PR Harrigan5, H Valdez1
Pfizer Inc, New York, NY, USA; 2Pfizer Inc, Collegeville, PA, USA; 3Pfizer Global Research and Development, Sandwich, UK; 4Pfizer PGRD New London, CT, USA; 5BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
|
| |
|
|
|
|
|
